Rebeccamed Medical Successfully Closes A++ Funding Round of Tens of Millions of Dollars

Rebeccamed Medical, a leading healthcare technology company, has recently announced the completion of a highly successful A++ funding round, raising tens of millions of dollars. The funding round was led by Mifang Health Fund, with participation from PwC. This significant investment will primarily be utilized to expand the global reach of Rebeccamed Medical's exclusive line of micro-radiofrequency products and to obtain regulatory approvals for new products in the Middle East, Americas, and Europe.

Rebeccamed Medical's Focus and Expertise:

Rebeccamed Medical specializes in the development of bio-compatible micro-electro-mechanical technology, with a strong emphasis on its clinical applications in fields such as urology, dermatology, and hepatology. The company boasts a team of experts encompassing various aspects of electronic engineering, clinical medicine, medical devices, and market development from both China and the United States. With over a decade of experience, Rebeccamed Medical has filed more than ten patent applications in the United States, Europe, and internationally, with several patents currently under review.

Advantages of Non-Silicon-Based Technology:

The trend in clinical treatment scenarios is shifting towards non-silicon-based technology. Traditional silicon-based micro-nano designs and production processes face limitations and are hindered by the constraints of the silicon chip industry. Moreover, silicon's poor biocompatibility restricts its application in disease treatments within the human body. Rebeccamed Medical has pioneered the development of 3D non-silicon-based micro-nano technology since 2007, successfully applying it in various fields, including healthcare, communication, and Internet of Things (IoT) applications. This technology's breakthrough lies in its ability to utilize organic and flexible materials, novel processing techniques, and the integration of advanced electronic packaging production lines, ensuring cost-effectiveness and scalability for future micro-nano technology applications in healthcare and electronic products.

OAB Micro-Radiofrequency Treatment Device:

One of Rebeccamed Medical's notable achievements is the development of the OAB micro-radiofrequency treatment device. This device combines disposable catheters with micro-radiofrequency equipment to provide neural radiofrequency therapy for the bladder neck, reducing neural sensitivity. Approved in 2020, it is currently the only domestically approved micro-radiofrequency treatment for OAB (overactive bladder) and the world's first micro-radiofrequency treatment product for OAB. Dr. Zhang Yang, the founder of Rebeccamed Medical, expressed gratitude to both new and existing shareholders for their strong support, emphasizing the company's commitment to prioritize patient well-being, technological innovation, and market agility.

Future Plans and Expansion:

In the increasingly competitive global medical device market, Rebeccamed Medical aims to further its technological advancements and market presence. The company plans to explore opportunities in Greater China, the Middle East, and Europe and aims to deliver satisfactory results to shareholders within the next two years. By promoting genuine original research and non-substitutable medical technologies, Rebeccamed Medical endeavors to contribute significantly to the healthcare industry and the well-being of humanity.

Rebeccamed Medical's successful A++ funding round marks a significant milestone in the company's growth and underscores its commitment to revolutionizing healthcare through cutting-edge micro-electro-mechanical technology. With its focus on non-silicon-based solutions and a team of experts, Rebeccamed Medical is poised to make a lasting impact in clinical treatments and electronic products. The funding secured will enable the company to expand its global footprint and obtain regulatory approvals, furthering its mission to provide innovative and effective medical solutions worldwide.